Alto Neuroscience (NYSE:ANRO) Sees Large Volume Increase - What's Next?

Key Points

• Trading volume surged 215% to approximately 1.29 million shares, while Alto Neuroscience shares last traded at $21.915, below the previous close of $22.09.
• Analyst sentiment remains generally positive: eight analysts rate the stock a Buy, two a Hold and one a Sell, producing a “Moderate Buy” consensus and an average price target of $37.25.
• The company exceeded quarterly earnings expectations, reporting a loss of $0.65 per share versus the projected $0.73 loss. However, CFO Nicholas Smith sold 110,830 shares worth about $2.95 million, reducing his personal stake by 82.16%.

Shares of Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) saw an uptick in trading volume on Wednesday. Approximately 1,292,736 shares were traded during trading, an increase of 215% from the previous session's volume of 410,061 shares. The stock last traded at $21.9150 and had previously closed at $22.09.

Wall Street Analyst Weigh In

ANRO has been the subject of several recent analyst reports. HC Wainwright raised their target price on shares of Alto Neuroscience from $50.00 to $55.00 and gave the company a "buy" rating in a research note on Monday, August 17th. Wedbush upped their price target on Alto Neuroscience from $24.00 to $26.00 and gave the stock a "neutral" rating in a research report on Thursday, August 13th. BTIG Research increased their price objective on Alto Neuroscience from $28.00 to $37.00 and gave the company a "buy" rating in a report on Thursday, August 13th. Wall Street Zen cut Alto Neuroscience from a "hold" rating to a "sell" rating in a research report on Saturday, September 12th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Alto Neuroscience in a research note on Wednesday, July 29th. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Alto Neuroscience currently has an average rating of "Moderate Buy" and a consensus target price of $37.25.

Alto Neuroscience Price Performance

The stock has a 50 day moving average of $30.55 and a 200-day moving average of $26.27. The company has a debt-to-equity ratio of 0.07, a quick ratio of 14.85 and a current ratio of 14.85. The company has a market cap of $847.98 million, a PE ratio of -8.89 and a beta of 1.31.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.08. Equities analysts predict that Alto Neuroscience, Inc. will post -2.68 earnings per share for the current year.

Insider Buying and Selling at Alto Neuroscience

In related news, CFO Nicholas Smith sold 110,830 shares of the stock in a transaction on Tuesday, September 29th. The stock was sold at an average price of $26.58, for a total value of $2,945,861.40. Following the completion of the transaction, the chief financial officer directly owned 24,060 shares of the company's stock, valued at approximately $639,514.80. This represents a 82.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.25% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Alto Neuroscience

Hedge funds have recently modified their holdings of the business. Quantinno Capital Management LP increased its stake in Alto Neuroscience by 1.4% during the first quarter. Quantinno Capital Management LP now owns 36,069 shares of the company's stock worth $811,000 after acquiring an additional 490 shares during the last quarter. Farther Finance Advisors LLC lifted its position in Alto Neuroscience by 48,581.8% in the third quarter. Farther Finance Advisors LLC now owns 5,355 shares of the company's stock valued at $137,000 after buying an additional 5,344 shares during the last quarter. Renaissance Technologies LLC lifted its position in Alto Neuroscience by 6.3% in the first quarter. Renaissance Technologies LLC now owns 103,499 shares of the company's stock valued at $2,327,000 after buying an additional 6,100 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Alto Neuroscience by 26.1% during the first quarter. Dimensional Fund Advisors LP now owns 39,324 shares of the company's stock worth $884,000 after buying an additional 8,148 shares during the period. Finally, GK Wealth Management LLC purchased a new position in Alto Neuroscience during the second quarter worth about $226,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with psychiatric and neurological disorders. The company seeks to use neuroscience, digital health tools and biological and behavioral biomarkers to identify patient subgroups that may respond to specific treatments.

Alto's pipeline has included investigational therapies for major depressive disorder and other central nervous system conditions. Its development programs are designed to address limitations of conventional psychiatric treatment by matching therapies to patient characteristics and measuring treatment response through objective data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.